---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-288885"
form_type: "8-K"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2021-10-01T23:59:59+00:00"
generated_at: "2026-06-28T23:58:22.196930+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Roivant Sciences closes SPAC merger with MAAC; trading starts Oct 1 on Nasdaq under ROIV

## Summary
- Post-close cash ~$2.5B; PIPE raised $220M from 22M shares at $10.00 each.
- Richard Pulik appointed CFO effective Sept 28, replacing Matt Gline who remains CEO; Pulik from Novartis.
- Pulik receives $400K salary, target 100% bonus, 220,015 RSUs, and options for 313,419 shares.

## SEC filing metadata
- accession: 0001193125-21-288885
- form_type: 8-K
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2021-10-01T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 3.02, 3.03, 5.03, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000119312521288885/0001193125-21-288885-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000119312521288885/d230641d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-288885
- JSON: https://secwatch.observer/filing/0001193125-21-288885.json
- Plain text: https://secwatch.observer/filing/0001193125-21-288885.txt

## Key facts
- Executive change
  Matthew Gline changed role as Principal Financial Officer and Chief Financial Officer at Roivant Sciences Ltd..
  - Action: stepped down
  - Role: Principal Financial Officer and Chief Financial Officer
  source text: Matthew Gline, who has been serving as Principal Financial Officer of the Company and Chief Financial Officer of RSI, will step down from those positions as of the Effective Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1635088/000119312521288885/0001193125-21-288885-index.htm
- Executive change
  Richard Pulik was appointed as Principal Financial Officer and Chief Financial Officer at Roivant Sciences Ltd..
  - Action: appointed
  - Role: Principal Financial Officer and Chief Financial Officer
  source text: On September 28, 2021 (the “Effective Date”), the Company appointed Richard Pulik as Principal Financial Officer of the Company and as Chief Financial Officer of the Company’s subsidiary, Roivant Sciences, Inc. (“RSI”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1635088/000119312521288885/0001193125-21-288885-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.